Suppr超能文献

美司钠与异环磷酰胺联合口服给药。

Oral administration of mesna with ifosfamide.

作者信息

Goren M P

机构信息

Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.

出版信息

Semin Oncol. 1996 Jun;23(3 Suppl 6):91-6.

PMID:8677457
Abstract

Mesna can be given orally to simplify outpatient ifosfamide therapy. Oral administration of mesna solution or tablets has been approved in Canada, Denmark, Germany, Italy, The Netherlands, and the United Kingdom, and programs for registration are ongoing in other European countries and in the United States. This review summarizes dosing schedules and the incidence of hematuria in 47 clinical studies, in which oral mesna was given to at least 1,986 patients who received more than 6,475 courses of ifosfamide. Various doses and schedules of oral mesna, usually in combination with intravenously injected mesna, provided effective uroprotection for a wide range of ifosfamide regimens.

摘要

美司钠可口服给药以简化门诊异环磷酰胺治疗。美司钠溶液或片剂的口服给药已在加拿大、丹麦、德国、意大利、荷兰和英国获得批准,其他欧洲国家和美国正在进行注册程序。本综述总结了47项临床研究中的给药方案和血尿发生率,其中至少1986例接受超过6475疗程异环磷酰胺治疗的患者口服了美司钠。各种口服美司钠的剂量和方案,通常与静脉注射美司钠联合使用,可为广泛的异环磷酰胺治疗方案提供有效的尿路保护。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验